Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 4/20 | 0.82 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.36 |
| ▸ | F3 | P13726 | 3/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.33 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913456 | 1.00 | TYR (0.82) | TYRSYNJ2F3PRKAG1PRKAA2 | |
| SCHEMBL12303842 | 1.00 | TYR (0.82) | TYRSYNJ2F3PRKAG1PRKAA2 | |
| SCHEMBL30542251 | 1.00 | TYR (0.82) | TYRSYNJ2F3PRKAG1PRKAA2 | |
| SCHEMBL17479915 | 1.00 | TYR (0.82) | TYRSYNJ2F3PRKAG1PRKAA2 | |
| SCHEMBL15826747 | 1.00 | TYR (0.82) | TYRSYNJ2F3PRKAG1PRKAA2 | |
| SCHEMBL14217990 | 1.00 | TYR (0.82) | TYRSYNJ2F3PRKAG1PRKAA2 | |
| SCHEMBL12764257 | 1.00 | TYR (0.82) | TYRSYNJ2F3PRKAG1PRKAA2 | |
| SCHEMBL19647513 | 1.00 | TYR (0.82) | TYRSYNJ2F3PRKAG1PRKAA2 | |
| SCHEMBL20636509 | 1.00 | TYR (0.82) | TYRSYNJ2F3PRKAG1PRKAA2 | |
| SCHEMBL9913455 | 0.95 | TYR (0.74) | TYRSYNJ2F3PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9248088-B2 | Compositions and methods for skin conditioning | TELOMERASE ACTIVATION SCIENCES, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150093455-A1 | COMPOSITIONS AND METHODS FOR INCREASING TELOMERASE ACTIVITY | HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (HK) | 2015-04-02 | — | — | US | disclosed |
| US-20070154435-A1 | Compositions and methods for skin conditioning | TELOMERASE ACTIVATION SCIENCES, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150093455-A1 | COMPOSITIONS AND METHODS FOR INCREASING TELOMERASE ACTIVITY | TERT, TERF2, POT1 | TYR 307/4885SYNJ2 3745/4885F3 435/4885 |
| US-20070154435-A1 | Compositions and methods for skin conditioning | CUTA, ACOX3, AREG | TYR 2369/4885SYNJ2 1960/4885F3 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.